ANI Pharmaceuticals, Inc.
ANIP
$70.10
-$0.14-0.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.90% | 37.03% | 43.78% | 48.87% | 38.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.90% | 37.03% | 43.78% | 48.87% | 38.68% |
| Cost of Revenue | 38.05% | 38.91% | 44.25% | 41.26% | 36.79% |
| Gross Profit | 26.61% | 35.85% | 43.49% | 53.86% | 39.83% |
| SG&A Expenses | 10.76% | 20.74% | 36.84% | 41.76% | 58.99% |
| Depreciation & Amortization | 1.52% | 17.79% | 34.97% | 51.52% | 41.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.05% | 27.43% | 38.04% | 43.13% | 45.89% |
| Operating Income | 265.19% | 223.78% | 142.14% | 165.55% | -29.87% |
| Income Before Tax | 1,066.89% | 520.99% | 531.26% | 773.73% | -141.54% |
| Income Tax Expenses | 855.89% | 466.66% | 573.01% | 2,522.09% | -153.42% |
| Earnings from Continuing Operations | 1,160.61% | 537.80% | 522.94% | 672.15% | -137.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,160.61% | 537.80% | 522.94% | 672.15% | -137.80% |
| EBIT | 265.19% | 223.78% | 142.14% | 165.55% | -29.87% |
| EBITDA | 80.25% | 80.14% | 70.73% | 85.89% | 8.47% |
| EPS Basic | 743.96% | 452.16% | 439.90% | 489.11% | -158.09% |
| Normalized Basic EPS | 637.92% | 697.86% | 393.15% | 637.78% | -52.43% |
| EPS Diluted | 699.75% | 434.12% | 422.18% | 458.77% | -160.92% |
| Normalized Diluted EPS | 632.28% | 681.29% | 379.93% | 642.43% | -53.42% |
| Average Basic Shares Outstanding | 5.80% | 4.80% | 3.79% | 2.78% | 2.60% |
| Average Diluted Shares Outstanding | 8.99% | 8.31% | 7.25% | 4.56% | 2.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.02% | 1.11% | 1.17% | 1.17% | -3.65% |